<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00301119</url>
  </required_header>
  <id_info>
    <org_study_id>8896</org_study_id>
    <secondary_id>NYU-H-8896-06-B</secondary_id>
    <nct_id>NCT00301119</nct_id>
    <nct_alias>NCT00212524</nct_alias>
  </id_info>
  <brief_title>Lung Cancer Biomarkers and Screening</brief_title>
  <acronym>NYULCBC</acronym>
  <official_title>NYU Lung Cancer Biomarker Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Screening tests that use biomarkers may help doctors find tumor cells early and&#xD;
      plan effective treatment for lung cancer.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying biomarkers in screening participants for lung&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Identify and validate biomarkers for the early detection of lung cancer in individuals&#xD;
           at low- or high-risk for smoking-related cancers.&#xD;
&#xD;
        -  Identify preneoplastic cellular changes and lesions in these patients.&#xD;
&#xD;
      OUTLINE: Participants are stratified according to lung cancer risk status (with or without&#xD;
      increased risk).&#xD;
&#xD;
      Group 1 (screening cohort): Participants complete a questionnaire and undergo pulmonary&#xD;
      function testing, multidetector chest CT scan, sputum induction, and phlebotomy.&#xD;
&#xD;
      Group 2 (rule-out lung cancer): Participants complete the same questionnaire and undergo the&#xD;
      same tests and scans as in group 1. Some participants may undergo fiberoptic bronchoscopy&#xD;
      based upon CT scan results with transbronchial or endobronchial biopsies. Some participants&#xD;
      may undergo lung resection. Tissue samples are collected from surgery or biopsy.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of participants will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2000</start_date>
  <completion_date type="Anticipated">May 2030</completion_date>
  <primary_completion_date type="Anticipated">May 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lung cancer diagnosis as measured by CT scan findings and pathology findings annually</measure>
    <time_frame>07/01/2015</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Precancerous lung nodules as measured by CT scan findings and pathology findings annually</measure>
    <time_frame>07/01/2015</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">6860</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>lung cancer screening cohort</arm_group_label>
    <description>observational only. no intervention. current, former and never smokers over age 50 without history of cancer, except for non melanoma skin cancer, no previous treatment with chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>r/o lung cancer</arm_group_label>
    <description>observational only. no intervention. patients with CT findings suspicious for lung cancer who are undergoing bronchoscopy and/or surgery.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood serum, plasma, urine, sputum, BAL, lung tissue, buccal swab&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        healthy subjects at risk for lung cancer and controls from community, private physician&#xD;
        referrals, local trade unions, employee health fairs, word of mouth and print&#xD;
        advertisements.&#xD;
&#xD;
        patient referrals from physician outpatient offices and inpatients with CT findings&#xD;
        suspicious for lung cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Screening Cohort&#xD;
&#xD;
               -  At high- or low-risk for lung cancer&#xD;
&#xD;
               -  Smoking history â‰¥ 20 pack years*&#xD;
&#xD;
                    -  With or without workplace exposure to asbestos&#xD;
&#xD;
          -  NOTE: * Participants with &lt; 20 pack years of smoking are eligible if 50 years of age&#xD;
             or older&#xD;
&#xD;
          -  Rule-Out Lung cancer group&#xD;
&#xD;
               -  Referred for evaluation of suspicious nodules with 1 of the following diagnoses:&#xD;
&#xD;
                    -  Lung cancer&#xD;
&#xD;
                    -  Nonmalignant nodules (control group)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  No prior malignancy except nonmelanoma skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James N. Tsay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James N Tsay, MD, MPH</last_name>
    <phone>212-598-6351</phone>
    <email>Jun-Chieh.Tsay@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ellen M Eylers, RN, MSN, MPH</last_name>
    <phone>212-263-6126</phone>
    <email>ellen.eylers@nyumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NYU Cancer Institute at New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William N. Rom, MD, MPH</last_name>
      <phone>212-263-6479</phone>
      <email>william.rom@med.nyu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Greenberg AK, Rimal B, Felner K, Zafar S, Hung J, Eylers E, Phalan B, Zhang M, Goldberg JD, Crawford B, Rom WN, Naidich D, Merali S. S-adenosylmethionine as a biomarker for the early detection of lung cancer. Chest. 2007 Oct;132(4):1247-52.</citation>
    <PMID>17934114</PMID>
  </results_reference>
  <results_reference>
    <citation>Greenberg AK, Lu F, Goldberg JD, Eylers E, Tsay JC, Yie TA, Naidich D, McGuinness G, Pass H, Tchou-Wong KM, Addrizzo-Harris D, Chachoua A, Crawford B, Rom WN. CT scan screening for lung cancer: risk factors for nodules and malignancy in a high-risk urban cohort. PLoS One. 2012;7(7):e39403. doi: 10.1371/journal.pone.0039403. Epub 2012 Jul 2.</citation>
    <PMID>22768300</PMID>
  </results_reference>
  <results_reference>
    <citation>Rom WN, Goldberg JD, Addrizzo-Harris D, Watson HN, Khilkin M, Greenberg AK, Naidich DP, Crawford B, Eylers E, Liu D, Tan EM. Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers. BMC Cancer. 2010 May 26;10:234. doi: 10.1186/1471-2407-10-234.</citation>
    <PMID>20504322</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 8, 2006</study_first_submitted>
  <study_first_submitted_qc>March 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2006</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>small cell lung cancer</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>smoker lung cancer screening</keyword>
  <keyword>low dose spiral CT screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

